Danaher Corporation (DHR) Director Sells $960,693.96 in Stock
Danaher Corporation (NYSE:DHR) Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares of the company’s stock, valued at approximately $9,501,679.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Danaher Corporation (NYSE DHR) traded down 0.33% during trading on Wednesday, reaching $90.65. The company’s stock had a trading volume of 2,794,256 shares. Danaher Corporation has a 12 month low of $76.27 and a 12 month high of $91.72. The company has a market cap of $62.97 billion, a P/E ratio of 28.93 and a beta of 1.03. The stock’s 50-day moving average is $86.91 and its 200 day moving average is $84.34.
Danaher Corporation (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 earnings per share. On average, equities analysts forecast that Danaher Corporation will post $3.99 EPS for the current fiscal year.
A number of research firms recently commented on DHR. Wells Fargo & Company began coverage on shares of Danaher Corporation in a research report on Thursday, July 13th. They issued a “market perform” rating and a $90.00 price objective for the company. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $83.00 price objective on shares of Danaher Corporation in a research report on Tuesday, September 26th. Jefferies Group LLC restated a “buy” rating and issued a $95.00 price objective on shares of Danaher Corporation in a research report on Friday, August 4th. Robert W. Baird upped their price objective on shares of Danaher Corporation from $87.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. Finally, BidaskClub cut shares of Danaher Corporation from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $93.31.
Several large investors have recently bought and sold shares of the company. First Manhattan Co. increased its position in shares of Danaher Corporation by 3.8% during the third quarter. First Manhattan Co. now owns 2,856,032 shares of the conglomerate’s stock worth $244,990,000 after acquiring an additional 104,592 shares in the last quarter. Rothschild Investment Corp IL increased its position in shares of Danaher Corporation by 52.7% during the third quarter. Rothschild Investment Corp IL now owns 18,507 shares of the conglomerate’s stock worth $1,588,000 after acquiring an additional 6,388 shares in the last quarter. Aperio Group LLC increased its position in shares of Danaher Corporation by 6.9% during the third quarter. Aperio Group LLC now owns 508,789 shares of the conglomerate’s stock worth $43,644,000 after acquiring an additional 32,860 shares in the last quarter. New England Research & Management Inc. bought a new stake in shares of Danaher Corporation during the third quarter worth about $262,000. Finally, Steinberg Global Asset Management increased its position in shares of Danaher Corporation by 11.6% during the third quarter. Steinberg Global Asset Management now owns 16,064 shares of the conglomerate’s stock worth $1,378,000 after acquiring an additional 1,665 shares in the last quarter. 75.66% of the stock is owned by institutional investors.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.